本帖最后由 老马 于 2013-3-13 13:43 编辑
) u) y$ Y( n. l4 \% H0 z# T4 a) b( w% X9 L* L" l$ _
健择（吉西他滨）+顺铂+阿瓦斯汀
, I1 k' D: P$ S8 [% z: P- Q9 [ Gemzar +Cisplatin + Avastin* r0 r- q9 h( b
http://annonc.oxfordjournals.org/content/21/9/1804.full* @$ j/ E! h$ D. ?
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 p- D7 X* ~) aPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ) E3 n; }% M3 S' C
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
3 u" T8 A9 T. p+ t3 X1 P" B
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 261)
' x5 y; D6 @1 @
华为网盘附件： T2 H4 A/ {7 F
【华为网盘】ava.JPG/ W* c; g3 A8 r
|
显身卡
